Business Wire

Toshiba’s Board of Directors Issues Statement

25.6.2021 18:07:00 EEST | Business Wire | Press release

Share

Toshiba Corporation (TOKYO: 6502) today announced that the newly elected Board of Directors of Toshiba has issued a statement.

The full text of the statement is as follows:

The newly elected Board of Directors of Toshiba Corporation acknowledges and respects the outcome of the vote at the Company’s Annual General Meeting of Shareholders today. Listening to shareholders’ concerns and responding to them is a critical responsibility of the Board.

Toshiba is in the middle of a period of considerable change, focused around an improvement in corporate governance, greater emphasis on capital management, increase in shareholder returns, and the rebuilding of trust and support from our shareholders. The Board of Directors has undergone considerable change as a result of the independent investigation report published on June 10th, 2021 and the voting at the Annual General Meeting this afternoon.

Today, the Board unanimously elected Satoshi Tsunakawa as Interim Chairperson of the Board. Mr. Tsunakawa brings to this role a deep understanding of Toshiba’s strategic capabilities and competitive advantages, as well as an objective view of its challenges and opportunities. Mr. Tsunakawa will provide stability for our customers and employees while enabling the Board to advance its commitment to constructive change.

The Board has resolved on a new composition of all board committees, focused on the skills and capabilities of the current members of the board. In the coming weeks, the Nomination Committee and other members of the Board and management will engage with Toshiba’s major stakeholders—our shareholders, management, employees and customers—to consider any additional changes that may be needed to achieve the best possible outcome for Toshiba’s stability, governance and future profitability.

There are several key areas to highlight as we move forward.

  • Toshiba’s employees and customers are critical to our long-term success as a company. We will seek to create stability and confidence in the future and increase our level of engagement and transparency.
  • We will look to identify a successor to our current Interim Chairman and CEO, Satoshi Tsunakawa. We will consider both internal candidates as well as external candidates in search of the highest possible capability given Toshiba’s large portfolio of businesses. We will solicit the help of one or more global executive search firms as we consider additional candidates to serve on the board.
  • We will expand the scope of Toshiba’s newly formed Strategic Review Committee (“SRC”). The SRC will undertake a full review of the current assets of the company and work with the management team to devise a business plan for the future that is focused on creating growth in total shareholder returns through share buybacks and dividends. The ability to create value for the long term will also require thoughtful and disciplined investments oriented around growth in areas capable of generating high returns on invested capital.
  • The SRC will also engage with potential strategic and financial investors in the Company or in its subsidiaries and various businesses. We believe it is important to engage with this investor base to understand what alternatives might be available to our shareholders and the related implications for our other stakeholders. We will approach this engagement with an open mind and as a benchmark of comparison against Toshiba’s own ability to generate profitable growth and high shareholder returns.
  • We will undertake a review of the corporate culture of Toshiba and look for ways to improve management and employee morale. It is critical that we avoid a repeat of any of the past scandals and financial problems Toshiba has suffered. We will consider opportunities to create a greater “ownership culture” across the company.

We are looking forward to a brighter future for Toshiba, one of Japan’s most important companies. Lastly, we would like to express our appreciation to our outgoing Chairman, Osamu Nagayama, for his time commitment and support of Toshiba over the past year.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media
Midori Hara / Takashi Ebina / Yoko Takagi
Media Relations Office
Corporate Communications Div.
Toshiba Corporation
media.relations@toshiba.co.jp

For Investors
Investor Relations Group
Planning & Investor Relations Office
Strategic Planning Div.
Toshiba Corporation
ir@toshiba.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye